CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma...
Phase 2
Westwood, Kansas, United States
(nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma...
Phase 2
Westwood, Kansas, United States and 5 other locations
The study population is advanced gastric, gastroesophageal, and esophageal adenocarcinoma participants who have failed upfront standard of c...
Phase 1, Phase 2
Kansas City, Kansas, United States and 7 other locations
This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy t...
Phase 2
Fairway, Kansas, United States and 1 other location
The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as...
Phase 3
Fairway, Kansas, United States and 164 other locations
participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...
Phase 1, Phase 2
Kansas City, Missouri, United States and 66 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Kansas City, Kansas, United States and 186 other locations
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at wa...
Phase 1
Westwood, Kansas, United States and 36 other locations
and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...
Phase 3
Kansas City, Missouri, United States and 165 other locations
Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C\*08:02-restricted T cell receptor (TCR), tar...
Phase 1
Fairway, Kansas, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal